Used in patients who are intolerant and/or resistant to two or more tyrosine kinase inhibitors used to treat accelerated or chronic phase CML.

For the treatment of scleroderma, cancer, and restenosis.

For the treatment of pancreatic cancer and appetite disorders.

For the potential treatment of various leukemias, including chronic myeloid leukemia (CML).

For the treatment of obesity, as an adjunct to a reduced-calorie diet and increased physical activity.

For the treatment of atrial fibrillation and irritable bowel syndrome (IBS).

For the treatment of patients with solid tumors.

Used to reduce hyperglycemia in type 2 diabetes mellitus.

For the treatment of malaria. Also under investigation for the modulation of multidrug resistance in cancer cells.

For the treatment of diabetes. It is specifically used for lowering post-prandial blood glucose levels thereby reducing the risk of macrovascular complications.

Used in combination with first- and second-line chemotherapy for the treatment of metastatic colorectal cancer and non-small cell lung cancer (NSCLC).

For the treatment of congestive heart failure.

For the treatment of solid tumors.

Clinical studies with edotecarin have shown activity in subjects with colorectal cancer, esophageal cancer and other solid tumors.

For the treatment of premature ejaculation.

For the treatment of symptoms associated with irritable bowel syndrome.

For use in combination treatment of HIV infection (AIDS).

For the treatment of HIV-1 infection in combination with other antiretroviral agents.

Bifeprunox is being evaluated for the treatment of schizophrenia, psychosis, and Parkinson's disease.

For the treatment of pain.